tigecycline · Pf Prism Cv · NDA 021821
Tygacil
Earliest generic entry, as listed
8 Oct 2030
Blocked by patent: US 8372995.
Listed patents · 3 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 8372995 | drug product · sets the listed date | 8 Oct 2030 |
| US 7879828 | drug product | 5 Feb 2029 |
| US 8975242 | drug product | 24 Oct 2028 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 021821 · 001 · RLD | powder, intravenous | 50MG/VIAL | 8 Oct 2030 |
Expired or delisted (3)
- US 10588975 · product · 13 Mar 2026
- US 9254328 · product · 13 Mar 2026
- US 9694078 · product · 13 Mar 2026